An Open-Label Randomized Study of Subcutaneous and Intravenous Velcade in Subjects With Previously Treated Multiple Myeloma.

Trial Profile

An Open-Label Randomized Study of Subcutaneous and Intravenous Velcade in Subjects With Previously Treated Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Johnson & Johnson; Millennium
  • Most Recent Events

    • 15 Mar 2012 Additional location (England) added as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual end date changed from Sep 2010 to Jan 2011 as reported by European Clinical Trials Database.
    • 15 Mar 2012 This trial is recruiting in France as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top